Cargando…

Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status

Detalles Bibliográficos
Autores principales:	Du, Lixin, Li, Zhigang, Lan, Peng, Huang, Huayu, Cheng, Wende
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485680/ https://www.ncbi.nlm.nih.gov/pubmed/36148068 http://dx.doi.org/10.3389/fcvm.2022.1011535

Ejemplares similares

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
por: Du, Lixin, et al.
Publicado: (2022)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
por: Longato, Enrico, et al.
Publicado: (2020)

Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study
por: Dzaye, Omar, et al.
Publicado: (2022)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021)

GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression
por: Qiu, Mei, et al.
Publicado: (2020)

SAT-LB013 The Effect of Select GLP1 Agonists and SGLT2 Inhibitors on the Unfolded Protein Response in Primary Human Coronary Artery Endothelial Cells
por: Kalidas, Poonam, et al.
Publicado: (2019)

Monitoring the Comparative Safety of SGLT2i vs GLP-1 RA in Older Adults With Type 2 Diabetes by Frailty Status
por: Kutz, Alexander, et al.
Publicado: (2021)

Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD
por: Shah, Hetal S., et al.
Publicado: (2018)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy
por: Xi, Yangbo, et al.
Publicado: (2022)

Alpha2-Antiplasmin: The Devil You Don't Know in Cerebrovascular and Cardiovascular Disease
por: Singh, Satish, et al.
Publicado: (2020)

GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis
por: Yan, Hongle, et al.
Publicado: (2022)

The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure
por: Ji, Peng‐juan, et al.
Publicado: (2023)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
por: Wu, Victor Chien-Chia, et al.
Publicado: (2022)

Commentary: Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Qiu, Mei, et al.
Publicado: (2021)

SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
por: Abdelgadir, Elamin, et al.
Publicado: (2018)

GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway
por: Mazzieri, Alessio, et al.
Publicado: (2023)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis
por: Capuano, Annalisa, et al.
Publicado: (2022)

SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Zhao, Zinan, et al.
Publicado: (2022)

Improving early diagnosis of cardiovascular disease in patients with type 2 diabetes and COPD: protocol of the RED-CVD cluster randomised diagnostic trial
por: Groenewegen, Amy, et al.
Publicado: (2021)

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
por: Sposito, Andrei C., et al.
Publicado: (2018)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
por: Menghini, Rossella, et al.
Publicado: (2023)

Exaggerated postural sway improves orthostatic cardiovascular and cerebrovascular control
por: Williams, Erin L., et al.
Publicado: (2023)

The role of ROS-induced pyroptosis in CVD
por: Tian, Kaijiang, et al.
Publicado: (2023)

Is There a Diabetes–Kidney–Heart Continuum? Perspectives From the Results of the Cardiovascular and Renal Outcome Clinical Trials With SGLT2 Inhibitors
por: Bao, Liwen, et al.
Publicado: (2021)

In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study
por: Cesaro, Arturo, et al.
Publicado: (2022)

Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
por: Sposito, Andrei C., et al.
Publicado: (2019)

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
por: Gourdy, Pierre, et al.
Publicado: (2023)

Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
por: Heile, Michael, et al.
Publicado: (2018)

Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials: Perspective on GLP-1 RA and SGLT-2i therapies
por: Ludwig, Lisa, et al.
Publicado: (2020)

Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM
por: Li, Lu-Feng, et al.
Publicado: (2021)

Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology
por: Wang, Anzhu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r0s3h3q1srabt1reoprvsmccc9